Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Study acronym: IMPACT MS
StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Jan 6, 2025, no change to tracked fieldsv7-v8
  2. Primary completion date: Dec 2025 to Dec 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jul 2026 to Jul 2027
    • Site details revised
    v6
  3. Study completion date: Dec 2025 to Jul 2026v5
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  6. Start date: Jul 2020 to Aug 30, 2020v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.
Trial Details
NCT Number NCT04466150
Lead Sponsor University of California, San Francisco
Collaborators: Genentech, Inc., Valhalla Foundation
Conditions
(from sponsor)		 Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov